Wide Ranks

LUMO

Lumos Pharma, Inc.

4.30

Top Statistics
Market Cap 37 M Forward PE -2.21 Revenue Growth 10271.40 %
Current Ratio 2.65 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -0.6570 Enterprise / Revenue 10.81 Price To Sales Trailing12 Months 16.87
Profitability
Profit Margins 0.00 % Operating Margins -1052.34 %
Balance Sheet
Total Cash 13 M Total Cash Per Share 1.56 Total Debt 172000
Total Debt To Equity 3.50 Current Ratio 2.65 Book Value Per Share 0.5680
All Measures
Short Ratio 80.00 % Message Board Id finmb_256380672 Shares Short Prior Month 285411
Return On Equity -1.73 City Austin Uuid bcffe56f-50ef-3693-86d2-3838602f9308
Previous Close 4.32 First Trade Date Epoch Utc 1 B Book Value 0.5680
Beta 0.3310 Total Debt 172000 Volume 110328
Price To Book 7.57 Fifty Two Week Low 1.37 Total Cash Per Share 1.56
Total Revenue 2 M Shares Short Previous Month Date 1 B Target Median Price 4.25
Max Age 86400 Sand P52 Week Change 0.3133 Operating Margins -1052.34 %
Target Mean Price 4.25 Net Income To Common -34916000 Short Percent Of Float 0.0143
Implied Shares Outstanding 8 M Trailing Peg Ratio None Last Fiscal Year End 1 B
Average Daily Volume10 Day 121150 Average Volume10days 121150 Total Cash 13 M
Next Fiscal Year End 1 B Revenue Per Share 0.2700 Held Percent Insiders 0.3269
Trailing PE 0.0000 Date Short Interest 1 B Most Recent Quarter 1 B
Regular Market Previous Close 4.32 Target Low Price 4.25 Gmt Off Set Milliseconds -18000000
Fifty Day Average 4.10 Open 4.31 Free Cashflow -19431624
State TX Dividend Yield 0.00 % Return On Assets -0.6964
Time Zone Short Name EST Trailing Eps -4.28 Day Low 4.30
Address1 4200 Marathon Boulevard Shares Outstanding 8 M Price Hint 4
Target High Price 4.25 Website https://lumos-pharma.com 52 Week Change 0.5035
Average Volume 82956 Forward Eps -2.16 Recommendation Key none
Compensation As Of Epoch Date 1 B Quick Ratio 210.50 % Is_sp_500 False
Regular Market Day High 4.34 Profit Margins 0.00 % Debt To Equity 3.50
Fifty Two Week High 4.58 Day High 4.34 Shares Short 89511
Regular Market Open 4.31 Industry Key biotechnology Earnings Growth 0.00 %
Enterprise To Revenue 10.81 Revenue Growth 10271.40 % Shares Percent Shares Out 0.0104
Operating Cashflow -31673000 Currency USD Time Zone Full Name America/New_York
Market Cap 37 M Is_nasdaq_100 False Zip 78756
Quote Type EQUITY Industry Biotechnology Long Name Lumos Pharma, Inc.
Regular Market Day Low 4.30 Held Percent Institutions 0.2427 Current Price 4.30
Address2 Suite 200 Enterprise To Ebitda -0.6570 Financial Currency USD
Current Ratio 2.65 Gross Margins 100.00 % Industry Disp Biotechnology
Number Of Analyst Opinions 2 Country United States Float Shares 5 M
Two Hundred Day Average 3.02 Enterprise Value 23 M Price To Sales Trailing12 Months 16.87
Forward PE -2.21 Regular Market Volume 110328 Ebitda -36308000
Exchange NGM
Go to Yahoo Finance Go to Seeking Alpha 
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of products and therapies for people with rare diseases.

Its primary product candidate is LUM-201, an oral growth hormone secretagogue ibutamoren, which is in Phase III clinical trial for the treatment of idiopathic pediatric growth hormone deficiency and other rare endocrine disorders.

The company has a clinical collaboration with Massachusetts General Hospital to evaluate oral LUM-201 in nonalcoholic fatty liver disease.

Lumos Pharma, Inc. is headquartered in Austin, Texas.